PFS
VYGR icon

Prospera Financial Services’s Voyager Therapeutics VYGR Stock Holding History

Prospera Financial Services’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-600
Closed -$5K – 2610
2022
Q1 		$5K Buy
+600
New +$2.68K ﹤0.01% 2284

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Prospera Financial Services's VYGR Position: Q2 2022 in Review

Prospera Financial Services sold out of Voyager Therapeutics (VYGR) in Q2 2022, closing a stake of 600 shares — an estimated $5K sold.

Prospera Financial Services first reported a position in VYGR in Q1 2022 and held it in 1 quarter. The position peaked at $5K in Q1 2022. 78 funds tracked by Wall St. Rank hold VYGR as of Q2 2022.

  • Prospera Financial Services reported no remaining Voyager Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Prospera Financial Services sold 600 Voyager Therapeutics shares in Q2 2022, an estimated $5K.
  • Prospera Financial Services first reported a position in Voyager Therapeutics in Q1 2022 and held it in 1 quarter.
  • Prospera Financial Services's Voyager Therapeutics position peaked at $5K in Q1 2022.
  • 78 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2022.

Based on Prospera Financial Services's 13F filing for Q2 2022, filed 8 Aug 2022.